Leukemia SPORE Publications


Project 1

Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS, West DA, Williams KE, Johnson AJ, Sablitzky F, Plass C, Byrd JC.  Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood 117:862-71, 2011. PMCID: PMC3035078.

Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, Rai KR, Larson RA, Byrd JC. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011 Apr 1;29(10):1349-55. Epub 2011 Feb 14.  PMID: 21321292 [PubMed - indexed for MEDLINE] PMCID: PMC3084002 [Available on 2012/4/1]

Project 2

Becker H, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures. J Clin Oncol 28:596-604, 2009. PMCID : PMC 2815994.

Marcucci G, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2010 May 10;28(14):2348-55. Epub 2010 Apr 5.PMID: 20368543 [PubMed - indexed for MEDLINE]

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Paschka P, Holland KB, Schwind S, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD. Mutations of the Wilms tumor 1 gene (<I>WT1</I>) in older patients with primary cytogenetically normal acute myeloid leukemia. Blood. 2010 Aug 5;116(5):788-92. Epub 2010 May 4.  PMID: 20442368 [PubMed - indexed for MEDLINE]

Metzeler KH, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011;29:1373-81. PMCID: PMC3084003.

Schwind S, et al Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28:5257-64. PMCID: PMC3018359.

Marcucci G, et al. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 2011;117:1121-9. PMCID: PMC3056468.

Schwind S, et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116:5660-9. PMCID: PMC3031412.

Whitman SP et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116:3622-6. PMCID: PMC2981481.

Liu S et al., Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010;17:333-47.  PMCID: PMC2917066.

Project 3

Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, and Byrd JC. (2009) The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukemia.  Br J Haematol. 144(6):848-55.  PMCID: PMC2776067.

Awan FT, Johnson AJ, Lapalombella R, Hu W, Lucas M, Fischer B, and Byrd JC. (2010) Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.  Leuk Lymphoma. 51(1):27-38.  PMID: 20055657; PMCID: not yet available.

Lapalombella R,  Andritsos L,  Liu Q, May SE,  Browning R, Pham LV, Blum KA, Blum W, Ramanunni A,  Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, Ford R, Jr, Rader C, Muthusamy N,  Johnson AJ, and Byrd JC. (2010) Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B Cells through a PI3-kinase dependent pathway. Blood. 115(13):2619-2629. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production

Herman SE, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, Zhang X, Lannutti BJ, Puri KD, Muthusamy N, Byrd JC, Johnson AJ. (2011), The role of phosphatidylinositol 3-kinase-{delta} in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.  Blood. 2011 Apr 21;117(16):4323-7. Epub 2011 Mar 4.  PMID: 21378270 [PubMed - indexed for MEDLINE] PMCID: PMC3087482 [Available on 2012/4/21]

Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. (2011), Bruton's tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011 Jun 9;117(23):6287-96. Epub 2011 Mar 21.  PMID: 21422473 [PubMed - indexed for MEDLINE] PMCID: PMC3122947 [Available on 2012/6/9]

W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC. (2010), Dose escalation of lenalidomide in relapsed or refractory acute leukemias.  J Clin Oncol. 28(33):4919-25.  PMCID: PMC3020696.

Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM Jr, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC. (2010). CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain engineered monoclonal antibody.  Blood. 115(6):1204-13.  PMCID: PMC2826232.

Project 4

Li H, Lu Y, Piao L, Wu J, Liu S, Marcucci G, Ratnam M, Lee RJ.  Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid.  Int J Pharm. 2010 Dec 15;402(1-2):57-63. Epub 2010 Sep 29.PMID: 20883757 PMCID: PMC2982872

Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol. 2010 Nov 20;28(33):4919-25. Epub 2010 Oct 18.  PMCID: PMC3020696.

Project 5

Lucas DM, Still PC, Pérez LB, Grever MR, Kinghorn AD. Potential of plant-derived natural products in the treatment of leukemia and lymphoma. Curr Drug Targets. 2010 Jul;11(7):812-22. Review.  PMCID: PMC2892601.

Gupta SV, Sass EJ, Davis ME, Edwards RB, Lozanski G, Heerema NA, Lehman A, Zhang X, Jarjoura D*, Byrd JC, Pan L, Chan KK, Kinghorn A, Phelps A, Grever MR, Lucas DM. Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells. AAPS J. 2011 Sep;13(3):357-64. Epub 2011 May 4.  PMID: 21538216 [PubMed - in process] PMCID: PMC3160166 [Available on 2012/5/4]



The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu